HIGHLIGHTS
- who: Hui Yang from the Department of Radiation, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China have published the paper: The Prognostic Role of Blood Inflammatory Biomarkers and EGFR Mutation Status in Stage IIIA/N2 Non-Small Cell Lung Cancer Patients Treated With Trimodality Therapy, in the Journal: (JOURNAL)
- what: The authors focused on the particular patient population of stage IIIA/N2 NSCLC treated with trimodality therapy and aimed to find potential blood inflammatory biomarkers as prognostic predictors and treatment indicators.
- future: Large-scale prospective studies are needed to confirm the results . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.